Treace Medical Concepts, Inc. Comprehensive Income
Treace Medical Concepts, Inc. (TMCI) reported Comprehensive Income of -$15.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-07
- Treace Medical Concepts, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$15.90M.
- Treace Medical Concepts, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$18.06M.
- Treace Medical Concepts, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$9.40M.
- Treace Medical Concepts, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$16.25M.
- Treace Medical Concepts, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$59.03M.
- Treace Medical Concepts, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$55.81M.
- Treace Medical Concepts, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$49.34M.
- Treace Medical Concepts, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$42.84M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.90M 10-Q · filed 2026-08-07 | -$33.96M 10-Q · filed 2026-08-07 | -$43.36M derived: sum of 3 quarters · filed 2026-08-07 | -$59.62M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$18.06M 10-Q · filed 2026-05-08 | -$27.46M derived: sum of 2 quarters · filed 2026-05-08 | -$43.72M derived: sum of 3 quarters · filed 2026-05-08 | -$61.12M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$25.66M derived: sum of 2 quarters · filed 2026-02-27 | -$43.06M derived: sum of 3 quarters · filed 2026-08-07 | -$59.03M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$16.25M 10-Q · filed 2025-11-06 | -$33.66M derived: sum of 2 quarters · filed 2026-08-07 | -$49.62M 10-Q · filed 2025-11-06 | -$50.22M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$17.41M 10-Q · filed 2026-08-07 | -$33.37M 10-Q · filed 2026-08-07 | -$33.96M derived: sum of 3 quarters · filed 2026-08-07 | -$49.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$15.96M 10-Q · filed 2026-05-08 | -$16.56M derived: sum of 2 quarters · filed 2026-05-08 | -$31.70M derived: sum of 3 quarters · filed 2026-05-08 | -$53.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$595.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$15.74M derived: sum of 2 quarters · filed 2026-02-27 | -$37.04M derived: sum of 3 quarters · filed 2026-02-27 | -$55.81M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$15.14M 10-Q · filed 2025-11-06 | -$36.44M derived: sum of 2 quarters · filed 2025-11-06 | -$55.21M 10-Q · filed 2025-11-06 | -$61.18M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$21.30M 10-Q · filed 2025-08-07 | -$40.07M 10-Q · filed 2025-08-07 | -$46.04M derived: sum of 3 quarters · filed 2026-02-27 | -$63.49M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$18.77M 10-Q · filed 2025-05-08 | -$24.74M derived: sum of 2 quarters · filed 2026-02-27 | -$42.19M derived: sum of 3 quarters · filed 2026-02-27 | -$54.62M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$23.42M derived: sum of 2 quarters · filed 2026-02-27 | -$35.85M derived: sum of 3 quarters · filed 2026-02-27 | -$49.34M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$17.45M 10-Q · filed 2024-11-05 | -$29.88M derived: sum of 2 quarters · filed 2024-11-05 | -$43.37M 10-Q · filed 2024-11-05 | -$47.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$12.43M 10-Q · filed 2024-08-06 | -$25.92M 10-Q · filed 2024-08-06 | -$30.36M derived: sum of 3 quarters · filed 2025-02-27 | -$42.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$13.48M 10-Q · filed 2024-05-07 | -$17.92M derived: sum of 2 quarters · filed 2025-02-27 | -$30.05M derived: sum of 3 quarters · filed 2025-02-27 | -$47.29M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$16.57M derived: sum of 2 quarters · filed 2025-02-27 | -$33.81M derived: sum of 3 quarters · filed 2025-02-27 | -$42.84M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$12.13M 10-Q · filed 2023-11-09 | -$29.37M derived: sum of 2 quarters · filed 2023-11-09 | -$38.40M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$17.23M 10-Q · filed 2023-08-09 | -$26.27M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | -$9.04M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$20.75M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | -$4.31M 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |